Comparative effectiveness research and outcomes of diabetes treatment

Affiliations

Editorial

Monika M Safford. JAMA. 2014.

. 2014 Jun 11;311(22):2275-6.

doi: 10.1001/jama.2014.4313.

No abstract available

Comment in

Insulin vs sulfonylureas for second-line diabetes treatment.
Roumie CL, Greevy RA, Griffin MR. Roumie CL, et al. JAMA. 2014 Oct 22-29;312(16):1694. doi: 10.1001/jama.2014.11126. JAMA. 2014. PMID: 25335156 Free PMC article. No abstract available.
Insulin vs sulfonylureas for second-line diabetes treatment--reply.
Safford MM. Safford MM. JAMA. 2014 Oct 22-29;312(16):1694-5. doi: 10.1001/jama.2014.11129. JAMA. 2014. PMID: 25335159 No abstract available.

Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR. Roumie CL, et al. JAMA. 2014 Jun 11;311(22):2288-96. doi: 10.1001/jama.2014.4312. JAMA. 2014. PMID: 24915260 Free PMC article.